Sibylla Biotech S.p.A. products

What makes us unique is the power of our computational platform, which enables us to reconstruct the series of conformational rearrangements underlying the process of protein folding at an atomistic level of detail.

In Silico: Identifying small molecules able to revolutionize drug discovery. The PPI-FIT technology allows the exploration of unique pharmacological targets represented by protein folding intermediates. This places Sibylla Biotech in the exclusive position of identifying hit/lead compounds with a mechanism of action never explored so far. In this direction, we have developed an ad-hoc virtual screening workflow to identify small molecules targeting pockets on the intermediate folding states. Depending on the project, hit identification is carried out using public and virtual chemical libraries (clinical/approved drugs, natural compounds, fragments, focused libraries, diverse libraries, etc) and partners’ proprietary libraries.

The PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting) technology, of which Sibylla is the exclusive licensee, is a paradigm shift in rational drug design. The basic task of drug design is to find a small molecule able to bind a biological target -such as a protein- so to modulate or block its activity. So far, almost all drug design has focused on the native structure of the target protein. Sibylla Biotech opens the gates of a completely different strategy: targeting the protein while it is still folding.

We are currently working on the hit-to-lead process for KRAS and Cyclin D1 (CCND1) proteins in the biology lab.